SCOTUS rules that antibodies cannot be monopolizedMay 18, 2023 - In a closely fought patent battle between PCSK9 rivals Amgen and Sanofi/Regeneron, the Supreme Court ruled unanimously on Thursday that Amgen cannot monopolize the market for any and every antibody that binds to areas of the sweet spot of PCSK9.
[This ruling could further impact the FTC's review/decision on Pfizer's proposed US$43 Billion acquisition of antibody drug conjugate (ADC) company Seagen]